Amneal Pharmaceuticals Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Biohaven Ltd. (BHVN) have performed compared to their sector so far this year.
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks
Today's article presents why Amneal should get my prior buy rating from September reaffirmed. Although some technical signals support a hold rather than bullishness, fundamental analysis shows several upside drivers, including a robust and growing drug portfolio. Despite negative equity, the company also raised its operating cash flow guidance for FY25.
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. ( AMRX ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Anthony DiMeo - Head of Investor Relations Chirag Patel - Co-Founder, Co-CEO, President & Director Chintu Patel - Co-Founder, Co-CEO & Director Anastasios Konidaris - Executive VP & CFO Conference Call Participants Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Leszek Sulewski - Truist Securities, Inc., Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division David Amsellem - Piper Sandler & Co., Research Division Presentation Operator Good morning and welcome to the Amneal Pharmaceuticals Third Quarter 2025 Earnings Call. I will now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
